Drug intelligence / Profile preview

LB-DTK-BKV

Development stage: Phase 2
Lead developer: LucasBio
Modality: Cell Therapies
Administration: Intravenous

Overview

LB-DTK-BKV is an investigational cell therapy consisting of BK virus-specific T cells (VSTs) developed by LucasBio. It is designed to treat BK virus-associated hemorrhagic cystitis (BKV-HC), a common and potentially severe complication in patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapy works by providing donor-derived or off-the-shelf T cells that specifically recognize and eliminate BK virus-infected cells, thereby reducing viral load and alleviating symptoms of hemorrhagic cystitis. It is currently being evaluated in Phase 1/2 clinical trials for pediatric, adolescent, and adult populations.

Other names: BK virus specific T cells

Beyond the preview

Go deeper on LB-DTK-BKV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB-DTK-BKV.

Explore the full profile